Rabbit monoclonal antibody against human CD69 protein and its application
By developing high specificity and high affinity anti-human CD69 protein rabbit monoclonal antibody, a dual-anti-sandwich enzyme-linked immunoassay system was constructed, which solved the problem of low detection sensitivity of CD69 protein in the existing technology, and achieved high accuracy of trace proteins Detection significantly improves the specificity and sensitivity of the detection.
Patent Information
- Application Number
- CN202410401705.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-03
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-04-03
AI Technical Summary
The existing CD69 protein in vitro ELISA kit has poor detection sensitivity, making it difficult to achieve accurate detection of trace proteins, and the antibody affinity is low, which cannot meet the needs of high specificity and high sensitivity.
A rabbit monoclonal antibody against human CD69 protein was developed, with high specificity and high affinity, and was used to build a dual-anti-sandwich enzyme-linked immunoassay system, which improved the specificity, accuracy and sensitivity of the detection and achieved trace amounts. High-precision detection of proteins.
High sensitivity, specificity and high accuracy detection of human CD69 protein is achieved, with the detection limit as low as 38.50pg/mL. It is suitable for qualitative or quantitative detection, significantly improving the detection signal-to-noise ratio and detection accuracy.
Smart Images

Figure CN118440198B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antibody preparation, in particular to rabbit monoclonal antibodies against human CD69 protein and applications thereof. Background Art
[0002] CD69, also known as activation inducer molecule (AIM), early activation antigen-1 (EA-1), Leu23, MLR-3 or BL Ac / p26, is the earliest membrane surface molecule expressed by lymphocyte activation. Human CD69 is a complete type II transmembrane glycoprotein composed of 199 amino acids, including a 40-residue intracellular region, a 21-residue transmembrane region and a 138-residue extracellular region. The extracellular region contains C-type lectin (Ca 2+ CD69 also belongs to the C-type lectin receptor family. In addition, CD69 is also a member of the natural killer cell (NK)-specific genetic factor complex family. The difference is that NKR-P1, Ly-49 and NKG2 molecules are only expressed on NK cells, while CD69 can be expressed on a variety of cells, indicating that CD69 has multiple characteristics.
[0003] CD69 is a known early activation molecule of immune cells. It plays an important role in the activation, proliferation and differentiation of various blood cells. It can be expressed on activated B cells, T cells, NK cells, macrophages, monocytes, granulocytes and thymocytes. CD69 is the earliest surface molecule expressed after T lymphocyte activation. After its expression, it can also serve as a cell co-stimulatory signal to promote further activation and proliferation of T cells. CD69 can trigger extracellular Ca 2+Influx, upregulate the secretion of intracellular cytokines such as TNF-α and IFN-γ, as well as the synthesis and expression of IL-2 and its receptors, enhance the activity of transcription factor AP-1, and enhance T cell proliferation through intracellular signal transduction. The characteristic of CD69, which is only expressed after cell activation, makes it a marker molecule for cell activation, so the detection of CD69 can well indicate the early activation state of T cells. The analysis of the activation state of immune cells by detecting the expression of CD69 has been widely carried out in human and mouse models. In recent years, studies on the structure, gene location, protein expression and biological function of CD69 antigen have shown that CD69 may be closely related to cell apoptosis while promoting cell activation; T cells with high expression of CD69 activated in vivo are prone to rapid spontaneous apoptosis in vitro. Therefore, CD69 is an important multi-directional immune regulatory molecule, which is related to the pathogenesis of blood system diseases and immune-related diseases. In the treatment of blood diseases and autoimmune diseases, it is expected to develop new immunotherapy methods targeting CD69.
[0004] Given the important regulatory role of CD69 in blood and immune diseases and its outstanding value as a biomarker in immune activation, it is of great significance to develop a highly sensitive and specific CD69 protein detection method. Currently, immunoassays such as enzyme-linked immunosorbent assay (ELISA) have been developed and widely used to quantitatively measure CD69 protein levels in plasma, serum, cell lysates, culture supernatants, and tissue samples. The core technology is antibodies that specifically recognize CD69. However, the CD69 in vitro ELISA kits currently on the market have the disadvantages of low antibody affinity and poor detection sensitivity, making it difficult to detect trace amounts of protein in samples. Therefore, there is an urgent need to develop highly sensitive monoclonal antibodies that can specifically recognize human CD69. Summary of the invention
[0005] In view of the above-mentioned problems existing in the prior art, the present invention provides rabbit monoclonal antibodies against human CD69 protein and applications thereof. The antibodies provided by the present invention have the advantages of high specificity, good affinity, strong anti-interference ability, etc., which are beneficial to improving the specificity, accuracy, sensitivity and signal-to-noise ratio of CD69 protein detection. The double antibody sandwich enzyme-linked immunosorbent assay system developed therewith has the advantages of high selectivity and specificity, low detection limit and wide linear range.
[0006] To achieve the above object, the present invention is specifically implemented through the following technical solutions:
[0007] In a first aspect, the present invention provides a rabbit monoclonal antibody against human CD69 protein, which is a first antibody or a second antibody, wherein: the amino acid sequences of the complementary determining regions CDR1-3 on the light chain variable region of the first antibody are respectively shown as SEQ ID NOs.3-5, and the amino acid sequences of the complementary determining regions CDR1-3 on the heavy chain variable region are respectively shown as SEQ ID NOs.8-10; the amino acid sequences of the complementary determining regions CDR1-3 on the light chain variable region of the second antibody are respectively shown as SEQ ID NOs.13-15, and the amino acid sequences of the complementary determining regions CDR1-3 on the heavy chain variable region are respectively shown as SEQ ID NOs.18-20.
[0008] Furthermore, the amino acid sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.7; the amino acid sequence of the light chain variable region of the second antibody is shown as SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.17.
[0009] Furthermore, the amino acid sequence of the light chain of the first antibody is shown as SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.6; the amino acid sequence of the light chain of the second antibody is shown as SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.16.
[0010] Furthermore, the first antibody or the second antibody is a full-length antibody or an antibody fragment; the antibody fragment is selected from at least one of a Fab fragment, a F(ab)2 fragment, a Fv fragment, a (Fv)2 fragment, a scFv fragment and a sc(Fv)2 fragment.
[0011] The second aspect of the present invention provides a nucleic acid molecule, which encodes the first antibody and / or the second antibody as described above.
[0012] The third aspect of the present invention provides a recombinant vector or host cell comprising a nucleic acid molecule encoding the first antibody and / or the second antibody as described above.
[0013] The fourth aspect of the present invention provides the use of the above-mentioned rabbit monoclonal antibody against human CD69 protein, the above-mentioned nucleic acid molecule, the above-mentioned recombinant vector or host cell in the preparation of a kit for immunodetection of human CD69 protein.
[0014] A fifth aspect of the present invention provides a kit for immunodetection of human CD69 protein, the kit comprising the first antibody and / or the second antibody as described above.
[0015] Furthermore, the kit is an enzyme-linked immunosorbent assay kit.
[0016] Furthermore, the kit is a double antibody sandwich ELISA kit, which includes the first antibody and the second antibody, wherein the first antibody is a capture antibody, and the second antibody coupled with a detectable label is a detection antibody.
[0017] The advantages and positive effects of the present invention are:
[0018] The first antibody and the second antibody provided by the present invention have the advantages of high specificity, good affinity, strong anti-interference ability, etc. for human CD69 protein, can reduce the background, false positive rate and false negative rate of immunoassay, and are conducive to improving the detection specificity, accuracy, sensitivity and signal-to-noise ratio, and provide core raw materials for the immunoassay of human CD69 protein. The human CD69 protein double antibody sandwich enzyme-linked immunosorbent assay system developed with the first antibody as the capture antibody and the second antibody as the detection antibody has the advantages of high selectivity and specificity, low detection limit and wide linear range, with a detection limit as low as 38.50 pg / mL, which can realize high-precision, high-specificity and high-sensitivity detection of human CD69 protein in the detection sample, especially trace protein level, and provides a powerful means for qualitative or quantitative detection of human CD69 protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0020] Figure 1 This is a graph showing the antibody titer of rabbit serum after rabbits were immunized with recombinant human CD69 protein in Example 1 of the present invention;
[0021] Figure 2 The vector map used to construct the rabbit monoclonal antibody expression vector in Example 1 of the present invention, from left to right are the pRB322 vector maps carrying the light chain constant region and the heavy chain constant region;
[0022] Figure 3 This is an affinity curve diagram of the binding of rabbit monoclonal antibody 11G7 to human CD69 protein in Example 2 of the present invention;
[0023] Figure 4 This is an affinity curve diagram of the binding of rabbit monoclonal antibody 10F10 to human CD69 protein in Example 2 of the present invention;
[0024] Figure 5This is the standard curve of the double antibody sandwich ELISA method established based on rabbit monoclonal antibody 11G7 and antibody 10F10 in Example 3 of the present invention. DETAILED DESCRIPTION
[0025] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0026] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.
[0027] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.
[0028] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art.
[0029] The meaning of the terms "including", "comprising", "containing", "having" and the like is non-restrictive, that is, other steps and other ingredients that do not affect the results can be added. The term "and / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" will be regarded as including the following situations: (i) A, (ii) B, and (iii) A and B. The terms "first", "second", etc. are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that such usage can be interchangeable under appropriate circumstances.
[0030] The terms "rabbit monoclonal antibody", "monoclonal antibody", "antibody" and "monoclonal antibody" and other similar terms have the same meaning and can be used interchangeably. Unless otherwise specified, they all refer to antibodies that specifically bind to human CD69 protein. The modifier "rabbit" indicates that the complementarity determining region (CDR) of the antibody is derived from a rabbit immunoglobulin sequence.
[0031] An antibody is an immunoglobulin molecule that can specifically bind to a target antigen or epitope through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. In the present invention, the term "antibody" should be interpreted in the broadest sense and includes different antibody structures, including but not limited to so-called full-length antibodies, antibody fragments, and their genetic or chemical modifications, as long as they exhibit the desired antigen binding activity. Among them, "antibody fragment" refers to one or more parts or fragments of a full-length antibody. In typical examples, antibody fragments include: Fab, Fab', F(ab)2, F(ab')2, Fv, (Fv)2, scFv, sc(Fv)2.
[0032] A typical antibody molecule (full-length antibody) consists of two identical light chains (L) and two identical heavy chains (H). Light chains can be divided into two types, namely κ chain and λ chain; heavy chains can be classified into five types, namely μ, δ, γ, α and ε chains, and antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. The amino acid sequences near the N-terminus of the heavy and light chains vary greatly, while the amino acid sequences of other parts are relatively constant. The regions near the N-terminus of the light and heavy chains where the amino acid sequences vary greatly are called variable regions (V), and the regions near the C-terminus where the amino acid sequences are relatively stable are called constant regions (C). The heavy chain variable region (VH) and the light chain variable region (VL) are usually the most variable parts of the antibody and contain antigen recognition sites. The VH and VL regions can be further subdivided into hypervariable regions (HVR) and framework regions (FR). The hypervariable regions are also called complementarity determining regions (CDRs), which are ring-shaped structures. The heavy chain CDR and the light chain CDR are closely together and cooperate with each other through the FR region, forming a surface that can complement the three-dimensional structure of the target antigen or epitope, which determines the specificity of the antibody and is the site where the antibody recognizes and binds to the antigen. The FR region is the more conservative part of VH and VL. They are generally in a β-folded configuration and are connected by three CDRs that form a connecting loop. Each VH and VL is usually composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0033] CDRs and FRs can be identified according to the Kabat definition, the Chothia definition, the accumulation of both the Kabat definition and the Chothia definition, the AbM definition, the contact definition, the IMGT unique numbering definition and / or the conformational definition, or any CDR determination method known in the art. As used herein, the Kabat numbering system is used to define.
[0034] The light chain constant region (CL) and the heavy chain constant region (CH) are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of antibodies. The length of CL of different types of Ig (κ or λ) is basically the same, but the length of CH of different classes of Ig is different, such as IgG, IgA and IgD include CH1, CH2 and CH3, while IgM and IgE include CH1, CH2, CH3 and CH4. The amino acid sequences of the heavy chain and light chain constant regions of antibodies are well known in the art.
[0035] The terms "monoclonal antibody" or "monoantibody" and the like are used interchangeably and refer to a homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in small amounts. "Monoclonal antibody" is highly specific, directed against a single antigen or epitope. "Monoclonal" indicates that the antibody is a feature obtained from a substantially homogeneous antibody population and should not be construed as limiting the source or preparation method of the antibody. In certain embodiments, monoclonal antibodies are prepared by hybridoma methods, phage display methods, yeast display methods, recombinant DNA methods, single cell screening, or single cell sequencing methods.
[0036] The term "specific binding" is a well-known term in the art, and a molecule exhibits "specific binding" if it reacts with a specific target antigen or epitope more frequently, more rapidly, longer lastingly, and / or with greater affinity than with other target antigens or epitopes. "Specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.
[0037] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.
[0038] The embodiment of the present invention provides a rabbit monoclonal antibody against human CD69 protein, wherein the rabbit monoclonal antibody is a first antibody and / or a second antibody, and the rabbit monoclonal antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region both comprise three complementary determining regions (CDRs), which are named CDR1, CDR2 and CDR3, respectively; wherein: the amino acid sequences of the light chain CDR1, light chain CDR2 and light chain CDR3 of the first antibody are shown in SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of the heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively; the amino acid sequences of the light chain CDR1, light chain CDR2 and light chain CDR3 of the second antibody are shown in SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of the heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 are shown in SEQ ID NO. NO.18, SEQ ID NO.19 and SEQ ID NO.20.
[0039] The complementary determining region (CDR) is the core sequence of the antibody, and its length and amino acid composition determine the specificity and affinity of the antibody binding antigen. The present invention uses commercial recombinant human CD69 protein (from Abclonal, item number RP00077) as an immunogen to immunize rabbits, and the first antibody and the second antibody prepared with the above CDR sequence can specifically recognize and bind to the naturally expressed human CD69 protein in plasma, serum, cell lysate and culture supernatant and tissue samples, as well as the recombinant human CD69 protein expressed by genetic engineering technology. The antibody has high specificity, good affinity, and strong anti-interference ability, which is conducive to reducing the background and false positive rate of immunoassay, improving detection specificity and accuracy, while enhancing the detection signal, reducing the false negative rate, and improving detection sensitivity and signal-to-noise ratio. The present invention provides core raw materials for the immunoassay method of CD69 protein, which is of great significance and good application prospects in clinical diagnosis and scientific research applications.
[0040] A double antibody sandwich enzyme-linked immunosorbent assay (double antibody sandwich ELISA) system was further developed using the above two antibodies, in which the first antibody was used as the capture antibody and the second antibody was used as the detection antibody. It has high selectivity, specificity and a low detection limit when detecting human CD69 protein, with the detection limit as low as 38.50 pg / mL, and has the advantages of a wide linear range. It can achieve high-precision, high-specificity and high-sensitivity detection of human CD69 protein in samples, especially trace protein levels, and provides a powerful detection means for qualitative or quantitative detection of human CD69 protein.
[0041] Optionally, the light chain variable region and the heavy chain variable region each include 4 framework regions (FRs), and the 4 FRs and 3 CDRs are arranged alternately in sequence to form a variable region. The amino acid sequence of the light chain variable region (VL) of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.7. The amino acid sequence of the light chain variable region (VL) of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.17.
[0042] Optionally, the rabbit monoclonal antibody of the present invention further comprises a light chain constant region and a heavy chain constant region, CL and VL constitute the light chain, and CH and VH constitute the heavy chain. The constant region of an antibody can usually be obtained by public query, such as: searching for rabbit IgG gamma C reign to obtain CH through the IMGT online database (www.imgt.org), and searching for rabbit IgG Kappa C reign to obtain CL.
[0043] Specifically, the amino acid sequence of the light chain (L chain) of the first antibody is shown in SEQ ID NO. 1, and the amino acid sequence of the heavy chain (H chain) is shown in SEQ ID NO. 6. The amino acid sequence of the light chain (L chain) of the second antibody is shown in SEQ ID NO. 11, and the amino acid sequence of the heavy chain (H chain) is shown in SEQ ID NO. 16.
[0044] It should be noted that the rabbit monoclonal antibody of the present invention can be a full-length antibody (having a typical Y-shaped molecular structure) or an antibody fragment. The antibody fragment refers to a polypeptide that substantially retains the same biological function or activity as the full-length form of the rabbit monoclonal antibody. Specifically, the antibody fragment includes the CDR region as described above, and more preferably has the variable region as described above, thereby retaining a complete antigen recognition and binding site, and can bind to the same antigen as the full-length antibody, especially to the same epitope. The antibody fragments include but are not limited to: (i) Fab fragments, which are monovalent fragments consisting of the variable region and the first constant region of each heavy chain and light chain; (ii) F(ab)2 fragments, which are bivalent fragments comprising two Fab fragments connected by a disulfide bridge in the hinge region; (iii) Fv fragments, which are composed of one heavy chain variable region and one light chain variable region of an antibody; (iv) (Fv)2 fragments, which are composed of two covalently linked Fv fragments; (v) scFv fragments, which are Fv fragments consisting of a single polypeptide chain, in which one heavy chain variable region and one light chain variable region are connected by a linker; (vi) sc(Fv)2 fragments, which are formed by connecting two heavy chain variable regions and two light chain variable regions by a linker, etc. These antibody fragments can be obtained by conventional techniques known in the art.
[0045] Yet another embodiment of the present invention provides a nucleic acid molecule, wherein the nucleic acid molecule encodes the first antibody and / or the second antibody as described above.
[0046] The nucleic acid molecule can be in the form of DNA (e.g., cDNA, genomic DNA, or synthetic DNA) or RNA (e.g., mRNA or synthetic RNA). DNA can be single-stranded or double-stranded, and can be a coding strand or a non-coding strand. The sequence of the nucleic acid molecule can be derived based on the amino acid sequence of the antibody by conventional means such as codon coding rules.
[0047] The full-length sequence of a nucleic acid molecule or a fragment thereof can usually be obtained by PCR amplification, recombination or artificial synthesis.
[0048] Another embodiment of the present invention provides a recombinant vector or host cell comprising a nucleic acid molecule encoding the first antibody and / or the second antibody as described above.
[0049] The starting vector for constructing the recombinant vector is any conventional vector in the art, as long as it can hold the nucleic acid molecule. Typical vectors include plasmids, viral vectors, bacteriophages, cosmids and minichromosomes. Plasmids are the most common vector forms, and therefore, in the context of the present invention, vectors and plasmids are used interchangeably. Vectors can be cloning vectors (i.e., used to transfer nucleic acid molecules to a host and multiply in a host cell) or expression vectors (i.e., containing necessary genetic elements to allow nucleic acid molecules inserted into the vector to be expressed in a host cell). Cloning vectors can include selection markers, and origins of replication that match the cell type specified by the cloning vector, while expression vectors include regulatory elements (such as promoters, enhancers) expressed in specified host cells. The nucleic acid molecules of the present invention can be inserted into a suitable vector to form a cloning vector or expression vector carrying the nucleic acid molecule. This is a well-known technique in the art and will not be described in detail herein.
[0050] The nucleic acid molecules encoding the heavy and light chains of the antibodies of the present invention can be constructed into two vectors, respectively, which can be introduced into the same or different host cells. When the heavy and light chains are expressed in different host cells, each chain can be separated from the host cells expressing them, and the separated heavy and light chains are mixed and incubated under suitable conditions to form antibodies. In other embodiments, the nucleic acid molecules encoding the heavy and light chains of the rabbit monoclonal antibodies of the present invention can also be cloned into a vector, and each nucleic acid sequence is connected to a suitable promoter downstream; for example, each nucleic acid sequence encoding the heavy and light chains can be operably connected to different promoters, or the nucleic acid sequences encoding the heavy and light chains can be operably connected to a single promoter, so that both the heavy and light chains can be expressed by the same promoter. The choice of expression vector / promoter depends on the type of host cell used to produce the antibody.
[0051] Recombinant vectors can be used to transform host cells using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with CaCl2 or MgCl2. If necessary, methods such as microinjection, electroporation or liposome packaging can also be used. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation, as well as microinjection, electroporation, liposome packaging, etc.
[0052] The host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples include bacterial cells of Escherichia coli, Streptomyces, and Salmonella typhimurium, fungal cells such as yeast, insect cells of Drosophila S2 or Sf9, CHO, COS7, 293 series cells, etc. After obtaining a host cell transformed with the vector described above, the cell can be cultured under suitable conditions to express a monoclonal antibody, which can then be separated to obtain a purified antibody.
[0053] In a preferred embodiment, the above-mentioned recombinant vector is a mammalian expression vector pBR322, and the host cell is a human kidney epithelial cell (293F cell).
[0054] Another embodiment of the present invention provides the use of the above-mentioned rabbit monoclonal antibody against human CD69 protein, the above-mentioned nucleic acid molecule, the above-mentioned recombinant vector or host cell in the preparation of a kit for immunodetection of human CD69 protein.
[0055] The advantages of using the method in preparing a kit for immunodetection of human CD69 protein are the same as the advantages of the rabbit monoclonal antibody against human CD69 protein described above over the prior art, and will not be described in detail here.
[0056] Based on the same inventive concept as above, an embodiment of the present invention further provides a kit for immunodetection of human CD69 protein, wherein the kit comprises the first antibody and / or the second antibody as described above.
[0057] The advantages of the kit for immunodetection of human CD69 protein are the same as the advantages of the rabbit monoclonal antibody against human CD69 protein described above over the prior art, and will not be elaborated here.
[0058] It should be noted that the first antibody and the second antibody can be used separately, together, or in pairs. In immunoassay, when used separately or together, the first antibody and / or the second antibody are used as a primary antibody or a capture antibody, and the sample to be tested is contacted with the first antibody and / or the second antibody, and then the antibody is detected. In some embodiments, the first antibody and / or the second antibody can be coupled to a detectable label, and the qualitative or quantitative detection of CD69 protein is achieved by analyzing the changes in the identifiable signals generated by the detectable label. In other embodiments, the first antibody and / or the second antibody (as a primary antibody or a capture antibody) of the anti-human CD69 protein is not labeled, and the detectable label is coupled to a secondary antibody (as a detection antibody) or other molecules that can bind to the primary antibody. For example, if the anti-human CD69 protein antibody is a rabbit IgG antibody, the secondary antibody can be an anti-rabbit IgG antibody, thereby generating a change in the identifiable signal by coupling the detectable label. When used in pairs, one of the first antibody and the second antibody is used as a primary antibody or a capture antibody, and the other is used as a secondary antibody or a detection antibody.
[0059] The above-mentioned detectable labels for producing identifiable signal changes include, but are not limited to: biotin, fluorescein, chemiluminescent groups, chemical fluorescent groups, fluorescent proteins, enzymes (such as horseradish peroxidase, acid phosphatase), colloidal gold, colored magnetic beads, latex particles, radionuclides, detection antibodies or combinations thereof.
[0060] The above-mentioned immunoassay methods include, but are not limited to, enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot assay (ELISPOT), immunohistochemistry (IHC), immunofluorescence (IF), immunoblotting (WB), flow cytometry (FC), etc. Therefore, the kit can be an enzyme immunoassay kit, an enzyme-linked immunosorbent assay kit, an enzyme-linked immunospot assay kit, an immunohistochemistry kit, an immunofluorescence assay kit, an immunoblotting assay kit or a flow cytometry assay kit. Immunoassay samples include naturally expressed CD69 proteins in plasma, serum, urine, cell lysates, cell culture fluids and tissue samples, as well as recombinantly expressed CD69 proteins.
[0061] Based on the fact that the first antibody and the second antibody recognize different antigen epitopes, in a preferred embodiment, the kit is a double antibody sandwich enzyme-linked immunosorbent assay kit, comprising a first antibody and a second antibody, wherein the capture antibody (primary antibody) is the first antibody and the detection antibody (secondary antibody) is the second antibody coupled to a detectable marker.
[0062] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or usually under the conditions recommended by the manufacturer.
[0063] Example 1 Preparation of rabbit monoclonal antibody against human CD69 protein
[0064] The immunogen used in this example is recombinant human CD69 protein (from Abclonal, catalog number RP00077), the amino acid sequence of which is shown in NCBI accession number NP_001772.1 (corresponding to Uniprot ID: Q07108), and the coding gene sequence is shown in NCBI accession number NM_001781.2.
[0065] The antibody preparation method is based on the monoclonal antibody development technology of single B lymphocyte screening, cloning and culture. Its technical route includes: first, a single antigen-specific B lymphocyte is isolated from the spleen of an immunized rabbit, and then the light chain and heavy chain variable region encoding genes of the antibody are extracted by specific primers, and they are constructed into expression vectors carrying light chain and heavy chain constant region encoding genes respectively. Finally, the expression vectors carrying complete light chain and heavy chain genes are transfected into 293F cells and cultured. The cell culture fluid is purified by protein A affinity to obtain candidate antibodies. Further, two rabbit monoclonal antibodies are screened by affinity testing and antigen epitope identification, which are named 11G7 and 10F10 respectively. The selected antibodies 11G7 and 10F10 are sequenced. The sequencing work is completed by Jinkairui Biotechnology Co., Ltd. The amino acid (AA) sequences of the two are shown in Table 1-2 respectively. For convenience of description, light chain complementary determining regions (CDRs) 1-3 are represented by LCDR1, LCDR2 and LCDR3, respectively, and heavy chain complementary determining regions (CDRs) 1-3 are represented by HCDR1, HCDR2 and HCDR3, respectively.
[0066] Table 1 Sequence information of rabbit monoclonal antibody 11G7 in this example
[0067]
[0068] Table 2 Sequence information of rabbit monoclonal antibody 10F10 in this example
[0069]
[0070]
[0071] The preparation method of rabbit monoclonal antibodies 11G7 and 10F10 specifically comprises the following steps:
[0072] 1. Animal immunization: Two New Zealand white rabbits were immunized with recombinant Human CD69 protein as the immunogen; each rabbit was immunized with 100 μg of the immunogen, and before the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant (purchased from Sigma) to make an emulsion, which was injected subcutaneously at multiple points on the rabbit's abdomen and back; after the first immunization, 100 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant (purchased from Sigma) to make an emulsion every 3 weeks, and injected subcutaneously at multiple points on the rabbit's abdomen and back for three booster immunizations. After three immunizations, rabbit serum samples were collected, and the serum was diluted 1:243000 and the titer (Serum dilution) against the Human CD69 protein was determined by the ELISA method. The serum titer detection chart is shown in Figure 1 In the figure, N14867 and N14868 are rabbit numbers, NC represents the control group without serum, and negative represents rabbit negative serum. 450nm For rabbits with a leukemia exceeding 0.2, 200 μg of the immunogen was injected subcutaneously at multiple points for booster immunization. Three days later, the animals were sacrificed and the spleens were removed.
[0073] 2. Isolate B lymphocytes from the spleen: Take out a culture dish in a safety cabinet aseptically, add 30-40mL of basal culture medium, put a cell sieve, take out the spleen and put it in the cell sieve, cut off the excess connective tissue and fat on the rabbit spleen tissue, cut the spleen tissue into pieces and put it into the cell sieve for grinding, take a clean grinding rod, and use the end of the pressing part to crush and grind the tissue. The ground cells will be filtered into the culture medium through the cell sieve and suspended in the culture medium; wash the cell sieve with 10mL of basal culture medium; collect the basal culture medium containing cells outside the cell sieve into a sterile 50mL centrifuge tube; centrifuge at room temperature at 400g for 5 minutes, discard the supernatant, retain the cells, and add 13mL of room temperature RBC red blood cell lysis solution (purchased from BioGems) was used. Cell clumps were gently dispersed with a pipette and timed for 1 minute to perform red blood cell lysis. After the time was completed, 37 mL of basal culture medium was added and mixed to terminate red blood cell lysis. The mixture was centrifuged at 400 g for 5 minutes at room temperature, the supernatant was discarded, and the cells were retained. 40 mL of basal culture medium stored at room temperature was added, and cell clumps were gently dispersed with a pipette to resuspend the cells to complete the first wash. The mixture was centrifuged at 400 g for 5 minutes at room temperature, the supernatant was discarded, and the cells were retained. 20 mL of room temperature basal culture medium was added, and cell clumps were gently dispersed with a pipette to resuspend the cells. The resuspended cells were filtered again through a cell sieve to remove clumped cells, and then the cells were counted.
[0074] 3. B lymphocyte sorting and culture: See the patent "Method for efficiently separating single antigen-specific B lymphocytes from spleen cells (publication number: CN110016462A, publication date: 2019-07-16)" and the patent "A B lymphocyte in vitro culture system and application (publication number: CN111518765A, publication date: 2020-08-11)".
[0075] 4. Cloning of the gene encoding rabbit monoclonal antibody: The supernatant of cultured B lymphocytes was used to identify positive clones that could bind to recombinant Human CD69 protein by antigen-coated ELISA. The cells of the positive clones were collected and lysed and then analyzed by Quick-RNA TM RNA was extracted according to the instructions of MicroPrep kit (purchased from ZYMO, catalog number R1051) and reverse transcribed into cDNA. Using cDNA as template, the naturally paired rabbit monoclonal antibody light chain variable region (VL) and heavy chain variable region (VH) were amplified from the cDNA of the corresponding positive clone by PCR. The PCR reaction system was as follows: 4 μL cDNA, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 12.5 μL 2×Gloria HiFi (from ABclonal, catalog number RK20717) and 6.5 μL H2O; the PCR amplification program included: 98℃ pre-denaturation for 30 s, followed by 40 cycles of 98℃ for 10 s, 64℃ for 30 s, and 72℃ for 30 s, and finally kept at 72℃ for 5 min. The obtained reaction solution was stored at 4℃. The primer pair sequences (5'-3') for amplifying the VL and VH genes are as follows, where F and R represent the forward and reverse primers, respectively:
[0076] VL-F: tgaattcgagctcggtacccATGGACACGAGGGCCCCCAC (see SEQ ID NO. 21);
[0077] VL-R: cacacacgatggtgactgTTCCAGTTGCCACCTGATCAG (see SEQ ID NO. 22);
[0078] VH-F: tgaattcgagctcggtacccATGGAGACTGGGCTGCGCTG (see SEQ ID NO. 23);
[0079] VH-R: gtagcctttgaccaggcagcCCAGGGTCACCGTGGAGCTG (see SEQ ID NO. 24).
[0080] 5. Production and purification of rabbit monoclonal antibodies: In order to obtain multiple rabbit monoclonal antibodies that recognize recombinant Human CD69 protein, the heavy chain genes and light chain genes of several rabbit monoclonal antibodies selected in the above steps are loaded onto expression vectors respectively. The specific operation is as follows: The mammalian cell expression vector pBR322 containing the rabbit monoclonal antibody light chain constant region (CL) and heavy chain constant region (CH) genes is linearized with NheI and XbaI restriction endonucleases respectively, and the amplified VL and VH genes with signal peptide genes upstream are purified, and then constructed upstream of the CL and CH genes of the expression vector pBR322 by homologous recombination. Sequencing is used to verify whether the expression vector is successfully constructed. The expression map of the mammalian expression vector pBR322 carrying the CL and CH genes is shown in Figure 2 In the figure, pRB322 origin and f1 origin are replication promoters in E. coli, Ampcillin is a plasmid resistance gene, CMV immearly promoter is a promoter in eukaryotes, SV40 PA terminator is a tailing signal, Light chain constant is the nucleic acid sequence of the light chain constant region (left), Heavy chain constant is the nucleic acid sequence of the heavy chain constant region (right). CL and CH genes were obtained by searching the IMGT online database (www.imgt.org) to obtain CH by searching rabbit IgG gamma C reign, and CL by searching rabbit IgG Kappa C reign.
[0081] The signal peptide of this embodiment can adopt the antibody expression signal peptide sequence commonly used in the art, such as the patent "Rabbit monoclonal antibody against human interferon α2 and its application (publication number: CN116063487A, publication date: 2023-05-05)" and the patent "High-affinity Human IL-5 rabbit monoclonal antibody and its application (publication number: CN115819578A, publication date: 2023-03-21)" The light chain variable region upstream has a signal peptide "MDTRAPTQLLGLLLLWLPGATF" or "MDTRAPTQLLGLLLLWLPGARC", and the heavy chain variable region upstream has a signal peptide "METGLRWLLLVAVLKGVQC".
[0082] The expression vectors containing the rabbit monoclonal antibody light chain gene and heavy chain gene verified by sequencing were transfected into 293F cells together, and cultured for 72-96 hours after transfection to obtain the supernatant containing the recombinant antibody that recognizes the recombinant human CD69 protein. Then, the rabbit monoclonal antibody was purified from the culture supernatant using protein A affinity gel resin (purchased from Tiandi Renhe, catalog number SA023100). 12% SDS-PAGE gel electrophoresis was used to verify that the antibody purity was >95% and the concentration was >2mg / mL. The purified antibody was divided and stored at -20°C for later use.
[0083] 6. Screening and identification of monoclonal antibodies: The antibody affinity and antigen recognition epitope of the multiple anti-human CD69 rabbit monoclonal antibodies obtained above were identified.
[0084] Monoclonal antibody affinity determination: The affinity of the obtained rabbit monoclonal antibody was preliminarily determined using the Gator biomolecular interaction analyzer from Probe Life. The antigen was recombinant Human CD69 protein, the concentrations used were 150nM and 75nM, and the concentration of the rabbit monoclonal antibody was 2μg / mL; by comparing the affinities of the various antibodies, the affinity constant ≤1×10 -9 of antibodies.
[0085] Identification of antigen recognition epitopes: performed using the Gator Prime device, using the Protein A Probe probe. The specific methods are as follows: 1) Pre-wet: Before use, shake and wet the ProA probe in the matching buffer at 1000rpm for 300sec; 2) Baseline 1: Place the Pro A probe in the buffer for starting point calibration to ensure that the probe is initially in a stable state, and process at 1000rpm for 60sec; 3) Loading: Immobilize the test antibody 11G7 on the ProA probe at a concentration of 1ug / mL, and immobilize the test antibody 10F10 on the Pro On probe A, the solidification concentration is 4μg / mL, and it is treated at 1000rpm for 60sec; 4) Baseline2: The probe after solidification of the antibody is placed in a buffer solution for shaking washing, and treated at 1000rpm for 60sec; 5) Association: The probe after solidification of the antibody is placed in 75nM and 150nM antigen diluents, respectively, to test the affinity of the antibody binding to the antigen under different molar concentration conditions, and treated at 1000rpm for 600sec; 6) Dissociation: When the antigen-antibody binding reaches saturation, the probe is transferred to the dissociation system to complete the dissociation process, and treated at 1000rpm for 600sec. By analyzing the pairing data between the two antibodies, two antibodies with high affinity are selected. That is, the antibody 11G7 and the antibody 10F10 of the present invention are obtained.
[0086] Example 2 Affinity test of rabbit monoclonal antibodies 11G7 and 10F10
[0087] The operation was the same as in Example 1, and the Gator biomolecular interaction analyzer of Probe Life Company was used for accurate determination. The affinity curves of antibodies 11G7 and 10F10 were shown in Figures 1 and 2. Figure 3-4 , where the ordinate represents the change in the thickness of the conjugate after the probe binds to the antibody and protein, the abscissa represents the binding time, the dark gray curve is the real-time binding value curve, and the light gray curve is the fitted average curve. The affinity constants calculated by curve fitting are shown in Table 3.
[0088] Table 3 Affinity-related parameter determination results of rabbit monoclonal antibodies 11G7 and 10F10
[0089] Rabbit monoclonal antibody <![CDATA[K off (1 / s)]]> <![CDATA[K on (1 / Ms)]]> <![CDATA[K D (M)]]> 11G7 <![CDATA[1.13×10 -3 ]]> <![CDATA[5.76×10 5 ]]> <![CDATA[1.96×10 -9 ]]> 10F10 <![CDATA[1.71×10 -4 ]]> <![CDATA[6.27×10 5 ]]> <![CDATA[2.73×10 -10 ]]>
[0090] Table 3 Dissociation coefficient K off The constant used to characterize the dissociation rate of antibody and antigen, the binding coefficient K on A constant used to characterize how quickly an antibody binds to its target, the affinity constant K D K off / K on The ratio of represents the equilibrium dissociation constant between the antibody and its antigen. As shown in Table 3, the affinity constant K of rabbit monoclonal antibody 11G7 and human CD69 protein is D 1.96×10 -9 (M), affinity constant K of rabbit monoclonal antibody 10F10 and human CD69 protein D 2.73×10 -10 (M) shows that rabbit monoclonal antibodies 11G7 and 10F10 have high affinity to recombinant Human CD69.
[0091] Example 3 Establishment of a double antibody sandwich ELISA method based on rabbit monoclonal antibodies 11G7 and 10F10
[0092] In this example, rabbit monoclonal antibodies 11G7 and 10F10 against human CD69 protein were used to establish a double antibody sandwich enzyme-linked immunosorbent assay method, comprising the following steps:
[0093] 1) Coating capture antibody 11G7: dilute antibody 11G7 to 2 μg / mL with 1× PBS, mix on a vortexer, add 100 μL / well to a 96-well microplate, cover with a cover film, and incubate in a 4°C refrigerator for 16-20 hours;
[0094] 2) Washing: After incubation, discard the liquid in the wells, wash the plate once with 1×PBST, add 300 μL of sample, let stand for 40 seconds, then discard the liquid in the wells and pat dry on flat paper;
[0095] 3) Blocking: Add 200 μL / well of E013 blocking solution (1×PBS containing 2% BSA, 5% sucrose, 0.05% Tween and 0.1% proclin300, pH 7.2) into the plate wells, cover with cover film, and block at 37°C for 2 h. After the blocking is completed, discard the blocking solution, pat the ELISA plate dry, place it in a 37°C oven to dry for 0.5-2 h, and take it out for use;
[0096] 4) Add antigen protein: dilute the recombinant human CD69 protein with diluent to the following concentrations: 3000, 1500, 750, 375, 187.5, 93.75, 46.875, 0 pg / mL, then add 100 μL / well to the ELISA plate in sequence, cover with cover film, and incubate at 37°C for 2 h;
[0097] 5) Washing: After incubation, discard the liquid in the wells, wash the plate three times with 1×PBST, add 300 μL of sample, let it stand for 40 seconds, then discard the liquid in the wells and pat dry on flat paper;
[0098] 6) Add detection antibody 10F10: dilute the biotin-labeled rabbit monoclonal antibody 10F10 (10F10-biotin) to 0.05 μg / mL, add 100 μL / well to the ELISA plate, cover with a cover film, and incubate at 37°C for 1 hour;
[0099] The 10F10-biotin treatment method includes: preparing a 1 mg / mL solution of the antibody 10F10, and preparing a 60 mg / mL solution of NHS-LC-biotin with DMSO; taking 200 μL of the 1 mg / mL antibody 10F10 solution, adding 10 μL of the 60 mg / mL NHS-LC-biotin solution; mixing and placing at room temperature for 30 minutes, and then adding 50 μg of 500 mM Tris solution (pH 9.0) to terminate the reaction; finally, adding a large amount of 1×PBS buffer at pH 7.4, and centrifuging with a centrifugal column with an exclusion limit of 30KD to remove excess biotin molecules and balance the buffer system;
[0100] 7) Washing: After incubation, discard the liquid in the wells, wash the plate three times with 1×PBST, add 300 μL of sample, let it stand for 40 seconds, then discard the liquid in the wells and pat dry on flat paper;
[0101] 8) Add SA-HRP: dilute 100×SA-HRP (horseradish peroxidase labeled streptavidin, purchased from Wuhan Sanying Biotechnology Co., Ltd., catalog number SA00001-0) concentrate 100 times, add 100 μL / well to the ELISA plate, cover with cover film, and incubate at 37°C for 0.5 h;
[0102] 9) Washing: After incubation, discard the liquid in the wells, wash the plate three times with 1×PBST, add 300 μL of sample, let stand for 40 seconds, then discard the liquid in the wells and pat dry on flat paper;
[0103] 10) Add TMB colorimetric solution: Add 3,3',5,5'-tetramethylbenzidine (TMB) colorimetric solution to the ELISA plate at 100 μL / well, cover with cover film, and incubate at 37°C for 15 min;
[0104] 11) Draw the standard curve: After the incubation is completed, take out the ELISA plate, add 50 μL of stop solution (1 mol / L hydrochloric acid) to each well, and immediately read the plate at 450nm and 630nm using an ELISA reader. 450nm Subtract OD 630nm The corrected absorbance values are shown in Table 4; with the concentration of Human CD69 protein as the horizontal axis, the corrected absorbance value Y1 (Y1 = OD 450nm -OD 630nm ) is used as the ordinate to draw a graph. The curve obtained by fitting the four-parameter Logistic curve is as follows: Figure 5 shown.
[0105] Table 4 Standard curve of double antibody sandwich ELISA method based on antibodies 11G7 and 10F10
[0106]
[0107] The average value of 16 0 wells + 2×SD was substituted into the standard fitting curve, and the sensitivity was calculated. The linear range of the double antibody sandwich ELISA method based on monoclonal antibodies 11G7 and 10F10 was 46.87-3000 pg / mL, and the linear R 2 =0.9985, and the detection sensitivity is 38.50pg / mL, which can meet the high-sensitivity and high-reliability detection of human CD69 protein with a content as low as 38.50pg / mL in the sample to be tested, and is applicable to a wide range of target protein concentrations in the sample to be tested, and can be accurately detected in the range of 46.87-3000pg / mL.
[0108] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A rabbit monoclonal antibody against human CD69 protein, characterized in that: is a first antibody or a second antibody, wherein: The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region of the first antibody are shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively; The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region of the second antibody are shown as SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, respectively.
2. The rabbit monoclonal antibody against human CD69 protein according to claim 1, characterized in that: The amino acid sequence of the light chain variable region of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7; The amino acid sequence of the light chain variable region of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.
17.
3. The rabbit monoclonal antibody against human CD69 protein according to claim 2, characterized in that: The amino acid sequence of the light chain of the first antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6; The amino acid sequence of the light chain of the second antibody is shown in SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.
16.
4. The rabbit monoclonal antibody against human CD69 protein according to claim 1, characterized in that: The first antibody or the second antibody is a full-length antibody or an antibody fragment; The antibody fragment is selected from at least one of a Fab fragment, a F(ab)2 fragment, a Fv fragment, a (Fv)2 fragment, a scFv fragment and a sc(Fv)2 fragment.
5. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the first antibody or the second antibody according to any one of claims 1 to 4.
6. A recombinant vector or host cell, characterized in that: Comprising the nucleic acid molecule as described in claim 5.
7. Use of the rabbit monoclonal antibody against human CD69 protein according to any one of claims 1 to 4, the nucleic acid molecule according to claim 5, or the recombinant vector or host cell according to claim 6 in the preparation of a kit for immunodetection of human CD69 protein.
8. A kit for immunodetection of human CD69 protein, characterized in that: The method comprises the first antibody and / or the second antibody according to any one of claims 1 to 4.
9. The kit for immunodetection of human CD69 protein according to claim 8, characterized in that: The kit is an enzyme-linked immunosorbent assay kit.
10. The kit for immunodetection of human CD69 protein according to claim 9, characterized in that: The kit is a double antibody sandwich ELISA kit, which includes the first antibody and the second antibody, wherein the first antibody is a capture antibody, and the second antibody coupled with a detectable label is a detection antibody.
